Geovax Labs Stock Today
| GOVX Stock | USD 2.22 0.02 0.89% |
Performance3 of 100
| Odds Of DistressOver 83
|
GeoVax Labs is trading at 2.22 as of the 18th of January 2025; that is 0.89 percent decrease since the beginning of the trading day. The stock's open price was 2.24. GeoVax Labs has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 29th of January 2023 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of April 1999 | Category Healthcare | Classification Health Care |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia. The company has 9.44 M outstanding shares of which 373.69 K shares are currently shorted by private and institutional investors with about 0.35 trading days to cover. More on GeoVax Labs
Moving against GeoVax Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
GeoVax Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | David Dodd | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGeoVax Labs can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GeoVax Labs' financial leverage. It provides some insight into what part of GeoVax Labs' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
GeoVax Labs (GOVX) is traded on NASDAQ Exchange in USA. It is located in 1900 Lake Park Drive, Smyrna, GA, United States, 30080 and employs 17 people. GeoVax Labs is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.14 M. GeoVax Labs conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.44 M outstanding shares of which 373.69 K shares are currently shorted by private and institutional investors with about 0.35 trading days to cover.
GeoVax Labs currently holds about 30.9 M in cash with (25.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25.
Check GeoVax Labs Probability Of Bankruptcy
Ownership AllocationThe market capitalization of GeoVax Labs is $21.14 Million. Roughly 88.66 (percent) of GeoVax Labs outstanding shares are held by general public with 0.52 % owned by insiders and only 10.82 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check GeoVax Ownership Details
GeoVax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alphamark Advisors, Llc | 2024-09-30 | 50.0 | |
| Bank Of America Corp | 2024-09-30 | 43.0 | |
| Global Retirement Partners, Llc. | 2024-09-30 | 27.0 | |
| Duncker Streett & Co Inc | 2024-09-30 | 24.0 | |
| Royal Bank Of Canada | 2024-09-30 | 4.0 | |
| Fmr Inc | 2024-09-30 | 1.0 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 266 K | |
| Geode Capital Management, Llc | 2024-09-30 | 56.7 K |
GeoVax Labs Historical Income Statement
GeoVax Stock Against Markets
GeoVax Labs Corporate Management
| CPA CPA | CFO Sec | Profile | |
| Mark Newman | Chief Officer | Profile | |
| Jeffrey Welch | Head Operations | Profile | |
| John Sharkey | Vice Development | Profile |
Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.